Navigation Links
Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
Date:3/25/2010

Mega Stock Picks (www.megastockpicks.com) gives it's top buy recommendation to Pozen, Inc (NasdaqGM: POZN) upon approval of it's FDA submitted drug, Vimovo.

New York, NY (PRWEB) March 25, 2010 -- Mega Stock Picks, a reputable internet-based free subscriber newsletter, announced today that they are initiating full coverage on pending FDA Approval of Vimovo by POZEN, Inc. (NasdaqGM: POZN). Sign up for Mega Stock Picks free subscriber newsletter at http://www.megastockpicks.com.

Widely known for its successful stock alerts which focus mainly on pharmaceutical and undervalued penny securities, Mega Stock Picks has issued a strong buy alert for POZN with a 6 month price target of 25.00. Mega Stock Picks has given POZN its strongest buy recommendation.

Pozen, Inc (POZN) is currently one of the top performing stocks in the small-to-mid cap biotechnology industry. We believe this company is well diversified and financially sound with current collaborations with GlaxoSmithKline (NYSE: GSK), over $46 million in cash available and potentially more coming in April 2010 from a collaboration and license agreement with AstraZeneca (NYSE: AZN) for the US approval of its pending FDA approved drug, Vimovo.

Vimovo, a combination pill of naproxen (Aleve) and immediate release esomeprazole (Nexium), for arthritis patients (the addition of esomeprazole reduces the risk of stomach ulcers), is up for FDA decision on April 30th, 2010 and Mega Stock Picks believes this exciting new drug will receive a positive response.

Mega Stock Picks has built a reputation on alerting the most successful Pharmaceutical stocks prior to FDA approval such as VNDA, KERX, and CTIC. To sign up for these alerts, please visit http://www.megastockpicks.com.

About POZEN, Inc.
POZEN Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has a collaboration agreement with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and a collaboration and license agreement with AstraZeneca for VIMOVO, a proprietary fixed dose combination of the proton pump inhibitor esomeprazole magnesium with the naproxen in a single tablet for the management of pain and inflammation associated with conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers. It also develops PA32540, a Phase III clinical trial product, which is a combination of a proton pump inhibitor and aspirin for the secondary prevention of cardiovascular disease in patients at risk for gastric ulcers. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

Megastockpicks.com (”website”) has not been compensated, rather they have initiated their own independent research on Pozen Inc. The website is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. You understand and acknowledge that there is a very high degree of risk involved in trading securities. The website, the authors, the publisher, and all affiliates of website assume no responsibility or liability for your trading and investment results. Factual statements on the website, or in its publications, are made as of the date stated and are subject to change without notice. It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Examples presented on Megastockpicks.com’s website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial adviser and tax adviser to determine the suitability of any investment. Please view full disclaimer at the website.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3776614.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. American Public Health Champion Receives 2010 Stockholm Water Prize
2. PROLOR Biotech Announces Sale of $24.4 Million of Common Stock
3. StockCross Trades for a Cure: Seventh Annual Trading for a Cure Day Set
4. Tickerspy.com Announces New Stock Index Tracking Chinese Healthcare Stocks
5. Are Stock Market Woes Bad for the Heart?
6. Micromet Announces Pricing of Public Offering of 10 Million Shares of Common Stock
7. Tuba City Regional Health Care Corporation Selects Stockell Healthcare to Deploy Patient Access and Revenue Cycle Management Solution
8. Yongye International to Present at the 22nd Roth OC Growth Stock Conference
9. Smart Balance to Present at Roth Growth Stock Conference
10. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference
11. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
Breaking Medicine Technology: